ScreenerHero

RNAZTransCode Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · transcodetherapeutics.com
2.870USD-10.59%Mkt Cap: 3.04M $P/E: —

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.04M $
Enterprise Value208.61M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.66M $
Revenue/Share—
Last Price2.870 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.95
PEG—
EV/EBITDA-8.26
EV/Revenue—
P/S—
P/B2.18
EPS (TTM)-41.82
EPS (Forward)-0.60
52W Range
2.8700% of range20.99
52W High20.99 USD
52W Low2.870 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.82%
ROA-21.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.52M $
CapEx (TTM)6.66K $
FCF Margin—
FCF Yield-444.03%
Net Debt-7.73M $
Net Debt/EBITDA0.31
Balance Sheet
Debt/Equity0.00
Current Ratio1.97
Quick Ratio1.55
Book Value/Sh1.365 USD
Cash/Share0.4950 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.06M
Float—
Insiders3.55%
Institutions0.44%
Short Interest
Short Ratio1.0d
Short % Float2.67%
Short % Out.2.67%
Shares Short28.25K
Short (prev mo.)52.82K
Technical
SMA 505.794 (-50.5%)
SMA 2007.822 (-63.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)25.77K
Avg Vol (10d)38.42K
Technical Indicators
RSI (14)26.7
MACD-0.9394
MACD Signal-0.8367
MACD Hist.-0.1026
BB Upper6.501 USD
BB Middle4.311 USD
BB Lower2.122 USD
BB Width101.56%
ATR (14)0.5927 USD
Vol Ratio (20d)1.53x